A Randomised, Double Blind, Two-Arm, Single Dose, Parallel Phase I Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (a proposed bevacizumab biosimilar drug) and EU-approved Avastin in Japanese Healthy Male Volunteers

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2020
This article has no abstract
Epistemonikos ID: 6b0fe9349c732022a78b1d963896919007c59c86
First added on: Apr 11, 2025